Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: July 8, 2021 Expiration: July 7, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
TG Therapeutics, Inc.
John M. Burke, MD
Nathan H. Fowler, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate current evidence and best practice recommendations plus patient-related and disease-related characteristics to select patients who are candidates to receive PI3K inhibitors for the treatment of R/R FL
  • Select appropriate PI3K inhibitor therapy for individual patients during the COVID-19 pandemic based on comorbidities, risk of exposure, adverse event profiles, and mode and frequency of administration
  • Describe key differences among available PI3K inhibitors regarding target, indication, clinical trial safety and efficacy data, and dosing and administration used for the treatment of R/R FL
  • Monitor for and manage adverse events of treatment in patients with R/R FL being treated with PI3K inhibitors to support quality of life and continuation of treatment
  • Apply emerging clinical trial findings on novel therapies when formulating treatment recommendations for PI3K inhibitors for patients with FL in the frontline and R/R settings

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Epizyme, Kura, MorphoSys, Roche/Genentech, and Verastem and fees for non-CME/CE services from BeiGene and Seattle Genetics.
Nathan H. Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nathan H. Fowler, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb and Novartis and consulting fees from Bristol-Myers Squibb, Gilead Sciences, Epizyme, and Roche.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists, hematologists, and other healthcare professionals who treat patients with follicular lymphoma.

Goal

The goal of this program is to improve the knowledge and competence of learners to optimally use PI3K inhibitor therapy in the management of patients with relapsed/refractory follicular lymphoma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2021, through July 07, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors
  • CME

Loading...
In this interactive recording of a live CCO webinar, experts discuss the expanding role of PI3K inhibitors in managing relapsed/refractory follicular lymphoma.
John M. Burke, MD
Nathan H. Fowler, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: July 8, 2021 Expiration: July 7, 2022

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of use of asparaginase-based treatments in young and older adults with acute lymphoblastic leukemia

Wendy Stock, MD
Program Director
Emily Curran, MD Dan Douer, MD person default Scott Howard, MD, MSc person default Stephen P. Hunger, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 24, 2022 Expired: January 23, 2023

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
TG Therapeutics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings